REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
None
Unable to provide written informed consent to participate in this study
Known coronary artery disease at recruitment
History of previous coronary artery disease
Inability to acquire interpretable CT images
Baker Heart and Diabetes Institute
Lead sponsor
Western Health, Australia
Collaborator
Northern Hospital, Australia
Collaborator
Menzies Institute for Medical Research
Collaborator
Peter MacCallum Cancer Centre, Australia
Collaborator
The Alfred
Collaborator